American Journal of Clinical Dermatology

Papers
(The median citation count of American Journal of Clinical Dermatology is 6. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)
ArticleCitations
Alcohol and Smoking Cessation as Potential Modulators for Smoking-Associated Psoriasis Risk in Postmenopausal Women: The Women’s Health Initiative212
The Current State of Systemic Therapy of Metastatic Uveal Melanoma164
Role of Inflammation and Cytokine Dysregulation in Depression in Patients with Inflammatory Skin Conditions111
Prognostic Biomarkers in Evolving Melanoma Immunotherapy95
Economic Burden of Chronic Hand Eczema: A Review91
Pyoderma Gangrenosum: An Updated Literature Review on Established and Emerging Pharmacological Treatments87
New Onset and Exacerbations of Psoriasis Following COVID-19 Vaccines: A Systematic Review85
Disease Duration in Patients Recruited to Psoriasis Phase III Trials: A Systematic Review84
The Burden of Pediatric Psoriasis: A Systematic Review81
Deciphering the Etiologies of Adult Erythroderma: An Updated Guide to Presentations, Diagnostic Tools, Pathophysiologies, and Treatments79
Stepping Down Treatment in Chronic Spontaneous Urticaria: What We Know and What We Don’t Know63
Predicting the Time to Relapse Following Withdrawal from Different Biologics in Patients with Psoriasis who Responded to Therapy: A 12-Year Multicenter Cohort Study61
Performance of Staging Systems for Non-head and Neck Cutaneous Squamous Cell Carcinoma59
Chlormethine Gel Versus Chlormethine Ointment for Treatment of Patients with Mycosis Fungoides: A Post-Hoc Analysis of Clinical Trial Data59
Efficacy and Safety of Tralokinumab Across Racial Subgroups in Adults with Moderate-to-Severe Atopic Dermatitis: Post Hoc Analysis of Phase III Trials59
Efficacy and Safety of Upadacitinib in Patients With Moderate-to-Severe Atopic Dermatitis: Phase 3 Randomized Clinical Trial Results Through 140 Weeks58
Agreement Between Nail Psoriasis Severity Index Scores by a Convolutional Neural Network and Dermatologists: A Retrospective Study at an Academic New York City Institution57
Patient-Reported Outcome Measures and Their Clinical Applications in Dermatology57
Obesity in Hidradenitis Suppurativa: Are GLP-1 Receptor Agonists the New Frontier?56
Pathophysiology of Generalized Pustular Psoriasis55
Efficacy and Safety of Nail Psoriasis Targeted Therapies: A Systematic Review52
Assessment of Efficacy and Safety Outcomes Beyond Week 16 in Clinical Trials of Systemic Agents Used for the Treatment of Moderate to Severe Atopic Dermatitis in Combination with Topical Corticosteroi52
Correction to: Real-Life Barriers to Diagnosis of Early Mycosis Fungoides: An International Expert Panel Discussion51
Disease Modification in Psoriasis: Future Prospects for Long-Term Remission51
Correction to: Long-term Effectiveness and Safety of Upadacitinib for Atopic Dermatitis in a Real-world Setting: An Interim Analysis Through 48 Weeks of Observation50
Comment on: “Is There a Role for Therapeutic Drug Monitoring in Patients with Hidradenitis Suppurativa on Tumor Necrosis Factor-α Inhibitors?”49
Drug Survival of Oral Retinoids in Hidradenitis Suppurativa: A Real-Life Cohort Study49
Safety of Baricitinib in Adults with Severe Alopecia Areata from Two Phase III Trials Over a Median of 2.3 Years and Up to 4 Years of Treatment47
Lessons Learned from Orthopedics: A Call to Action for More Rigorous Platelet-Rich Plasma Hair Loss Clinical Trials44
Candida Infection Associated with Anti-IL-17 Medication: A Systematic Analysis and Review of the Literature43
Skin Cancer in People of Color: A Systematic Review42
Real-World Evidence on Dose Spacing of IL-23 Inhibitors in the Treatment of Psoriasis42
Systemic Treatments in Moderate-to-Severe Atopic Dermatitis in Pediatric Patients up to 12 Years of Age: Real-World Treatment Outcomes from the PEDISTAD Registry42
Truncal Acne and Scarring: A Comprehensive Review of Current Medical and Cosmetic Approaches to Treatment and Patient Management42
A Practice Approach to Acne Fulminans in Adolescents41
Ethnic Differences of Palmoplantar Pustulosis: A Systematic Review39
Atopic Dermatitis: Fertility, Pregnancy, and Treatment Perspectives39
Real-World Evidence of Tralokinumab Effectiveness and Safety: A Systematic Review and Meta-analysis39
Biomarkers in Atopic Dermatitis: A Review of the Role of IL-13 and the Impact of Tralokinumab Treatment38
Correction to: AtopyReg®, the Prospective Italian Patient Registry for Moderate-to-Severe Atopic Dermatitis in Adults: Baseline Demographics, Disease Characteristics, Comorbidities, and Treatment Hist38
The Use of Biologic Agents for the Treatment of Cutaneous Immune-Related Adverse Events from Immune Checkpoint Inhibitors: A Review of Reported Cases36
Long-Term Safety and Tolerability of Beremagene Geperpavec-svdt (B-VEC) in an Open-Label Extension Study of Patients with Dystrophic Epidermolysis Bullosa36
A Review of the Etiologies and Key Clinical Features of Secondary Hyperhidrosis34
Oral Lichen Planus: An Update on Diagnosis and Management34
Multiple Keratoacanthomas Associated with Genetic Syndromes: Narrative Review and Proposal of a Diagnostic Algorithm34
Scratching the Surface: A Comprehensive Guide to Understanding and Managing Vulvovaginal Itching34
Management and Long-Term Outcomes of Drug Reaction with Eosinophilia and Systemic Symptoms (DReSS) in Children: A Scoping Review33
Patient and Public Involvement in Dermatology Research: A Review32
Merkel Cell Carcinoma: Integrating Epidemiology, Immunology, and Therapeutic Updates31
Frontal Fibrosing Alopecia: An Update30
Commentary on “Patient-Reported Outcome Measures and Their Clinical Applications in Dermatology”29
Tree-Based Machine Learning to Identify Predictors of Psoriasis Incidence at the Neighborhood Level: A Populational Study from Quebec, Canada29
Individualized Neoantigen-Directed Melanoma Therapy28
Differential Diagnosis, Prevention, and Treatment of mpox (Monkeypox): A Review for Dermatologists27
Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2)27
The Burden of Acne Vulgaris on Health-Related Quality of Life and Psychosocial Well-Being Domains: A Systematic Review27
JAK Inhibitors and Inflammatory Nail Disorders: A Systematic Review of Clinical Outcomes and Therapeutic Potential27
AtopyReg®, the Prospective Italian Patient Registry for Moderate-to-Severe Atopic Dermatitis in Adults: Baseline Demographics, Disease Characteristics, Comorbidities, and Treatment History26
Efficacy and Safety of Dupilumab Maintained in Adults ≥ 60 Years of Age with Moderate-to-Severe Atopic Dermatitis: Analysis of Pooled Data from Four Randomized Clinical Trials26
Advancing Precision Medicine in Inflammatory Skin Disease26
Safety and Effectiveness of Upadacitinib in Patients with Moderate-to-Severe Atopic Dermatitis Who Smoke: a 2-Year Real-Life Multicenter Study26
Targeting Inflammation in Acne: Current Treatments and Future Prospects25
Comment on: “Eyebrow and Eyelash Alopecia: A Clinical Review”25
Autoimmune and Cutaneous Inflammatory Comorbidities in Adult-Onset Morphea in the All of Us Research Program25
Safety of Alopecia Treatments in Patients with Breast Cancer and High-Risk Women: A Review24
Intravenous Immunoglobulin Therapy for Pyoderma Gangrenosum: A Multicenter Retrospective Analysis in 81 Patients24
Management of Acne in Pregnancy24
Acknowledgement to Referees24
Exploring Suzetrigine's Role in Dermatologic Surgery: A Novel Nonopioid Analgesic for Postoperative Pain Management24
Burden to Partners of People with Psoriasis: Results from the FamilyPso International Study24
Long-Term Safety and Efficacy of Risankizumab to Treat Moderate-to-Severe Plaque Psoriasis: Final LIMMitless Phase 3, Open-Label Extension Trial Results23
Approach to the Atypical Wound23
Pembrolizumab for the First-Line Treatment of Recurrent Locally Advanced or Metastatic Merkel Cell Carcinoma: Results from the Single-Arm, Open-Label, Phase III KEYNOTE-913 Study22
Beyond the Herald Patch: Exploring the Complex Landscape of Pityriasis Rosea22
Identifying and Treating Ocular Manifestations in Psoriasis22
Impact of Generalized Pustular Psoriasis from the Perspective of People Living with the Condition: Results of an Online Survey22
Real-Life Barriers to Diagnosis of Early Mycosis Fungoides: An International Expert Panel Discussion 22
Systemic Versus Topical Corticosteroids in the Treatment of DRESS: A Retrospective Cohort Study Followed by a Meta-Analysis22
Cutaneous Small Vessel Vasculitis: A Practical Guide to Diagnosis and Management22
Publisher Correction to: Efficacy and Safety of Dupilumab Maintained in Adults ≥ 60 Years of Age with Moderate-to-Severe Atopic Dermatitis: Analysis of Pooled Data from Four Randomized Clinical Trials21
Real-World Use of Ruxolitinib Cream: Safety Analysis at 1 Year21
Is There a Place for Biologics in Acne?21
Dupilumab Facial Redness/Dupilumab Facial Dermatitis: A Guide for Clinicians21
Treatment Strategies for Chronic Pruritus and Eczema/Dermatitis in Older Adults Under the Category of Chronic Eczematous Eruptions of Aging (CEEA)20
The 25th World Congress of Dermatology, Singapore, 3–8 July, 2023: Research Highlights20
Interpreting the Relationship Among Itch, Sleep, and Work Productivity in Patients with Moderate-to-Severe Atopic Dermatitis: A Post Hoc Analysis of JADE MONO-220
Autoimmune, Autoinflammatory Disease and Cutaneous Malignancy Associations with Hidradenitis Suppurativa: A Cross-Sectional Study19
Disease Burden and Treatment Patterns Among US Patients with Hidradenitis Suppurativa: A Retrospective Cohort Study19
Treatment of Psoriasis Patients with Latent Tuberculosis Using IL-17 and IL-23 Inhibitors: A Retrospective, Multinational, Multicentre Study19
Oral Minoxidil for Alopecia Treatment: Risks, Benefits, and Recommendations18
An Update on New and Existing Treatments for the Management of Melasma18
Safety of Hydroxychloroquine: What a Dermatologist Should Know18
Melanoma Brain Metastases: An Update on the Use of Immune Checkpoint Inhibitors and Molecularly Targeted Agents17
Comment on: “Isotretinoin Exposure and Risk of Inflammatory Bowel Disease: A Systematic Review with Meta-Analysis and Trial Sequential Analysis”17
Comprehensive and Updated Algorithm of Hidradenitis Suppurativa Management from the Experts17
Review of Laser Treatments for Post-Inflammatory Hyperpigmentation in Skin of Color17
Patient Care Outcomes in Hospitalized Patients with Acute Generalized Exanthematous Pustulosis: A Cross-Sectional Database Study16
Review of an Anti-CD20 Monoclonal Antibody for the Treatment of Autoimmune Diseases of the Skin16
Diagnosis and Management of Dermatologic Adverse Events from Systemic Melanoma Therapies16
Correction to: Authors’ Reply to Chen and Chen: Comment on: “Isotretinoin Exposure and Risk of Inflammatory Bowel Disease: A Systematic Review with Meta-Analysis and Trial Sequential Analysis”16
Abscopal Effects and Immunomodulation in Skin Cancer Therapy16
Treatment of Hyperhidrosis: An Update15
Clinical Effectiveness and Safety of Initial Combination Therapy with Corticosteroids and Rituximab in Bullous Pemphigoid: A Retrospective Cohort Study15
Real-World Effectiveness, Safety, and Drug Survival of Risankizumab in Adult Patients with Plaque Psoriasis: A 3-Year Multicenter Retrospective Cohort Study15
Update in Diagnosis and Management of Primary Cutaneous B-Cell Lymphomas15
Evaluation of the Tolerability of Hedgehog Pathway Inhibitors in the Treatment of Advanced Basal Cell Carcinoma: A Narrative Review of Treatment Strategies15
Safety of Lebrikizumab in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: An Integrated Analysis of Eight Clinical Trials14
Pharmacokinetics of Roflumilast Cream in Chronic Plaque Psoriasis: Data from Phase I to Phase III Studies14
Real-World Experience of Bimekizumab for Plaque Psoriasis in Adult Patients with Prior Exposure to Interleukin-23 Inhibitors: A Multicenter Retrospective Study14
Correction to: Mastocytosis in the Skin: Approach to Diagnosis, Evaluation, and Management in Adult and Pediatric Patients14
KECORT Study: An International e-Delphi Study on the Treatment of KEloids Using Intralesional CORTicosteroids in Clinical Practice13
Atopic Dermatitis Across Shades of Skin13
Management of Coexisting Bullous Pemphigoid and Psoriasis: A Review13
The Skin and Gut Microbiome in Hidradenitis Suppurativa: Current Understanding and Future Considerations for Research and Treatment13
Automated Facial Acne Lesion Detecting and Counting Algorithm for Acne Severity Evaluation and Its Utility in Assisting Dermatologists13
Human Inborn Errors of Immunity in Pyoderma Gangrenosum: A Systematic Review13
Lichen Planus: What is New in Diagnosis and Treatment?13
New Practical Aspects of Sweet Syndrome13
Blue Nail Discoloration: Literature Review and Diagnostic Algorithms12
Oral Roflumilast in Patients with Psoriasis: A Real-World Cohort Study12
Lichen Simplex Chronicus: Clinical Perspectives and Emerging Therapeutic Strategies12
Correction to: The PROVe Study: US Real-World Experience with Chlormethine/Mechlorethamine Gel in Combination with Other Therapies for Patients with Mycosis Fungoides Cutaneous T-Cell Lymphoma12
Bimekizumab Complete Clearance of Both Skin and Nail Psoriasis: Comparative Efficacy in Phase III/IIIb Studies12
Alopecia in Children with Cancer: A Review from Pathophysiology to Management11
Diagnosis of Generalized Pustular Psoriasis11
Suggestions for a New Clinical Classification Approach to Panniculitis Based on a Mayo Clinic Experience of 207 Cases11
Dapsone Use in Dermatology11
Efinaconazole in Onychomycosis11
Meat Allergy: A Ticking Time Bomb11
Cholestatic Itch: Our Current Understanding of Pathophysiology and Treatments11
Cutaneous Manifestations of Inflammatory Bowel Disease: A Basic Overview11
Ruxolitinib Cream 1.5%: A Review in Mild to Moderate Atopic Dermatitis10
Clinical Assessment of Alopecia Areata Severity and Validating the Patient Experience: A Vodcast10
What’s New in Therapy for Male Androgenetic Alopecia?10
Long-Term Safety and Efficacy of Roflumilast Foam 0.3% in Patients with Seborrheic Dermatitis: A Phase II, Open-Label Trial of up to 52 Weeks10
Ultrasound Surveillance in Melanoma Management: Bridging Diagnostic Promise with Real-World Adherence: A Systematic Review and Meta-Analysis10
Eyebrow and Eyelash Alopecia: A Clinical Review10
Management of Erythrodermic Psoriasis with Systemic Therapies: A Systematic Review10
Correction to: Adherence to Hidradenitis Suppurativa Treatment10
Switching Between Adalimumab Reference Product and BI 695501 in Patients with Chronic Plaque Psoriasis (VOLTAIRE-X): A Randomized Controlled Trial9
Cellulitis in Pediatric Patients: Recognition and Management in the Era of Evolving Resistance9
Chronic Prurigo Including Prurigo Nodularis: New Insights and Treatments9
Alopecia Areata: Current Treatments and New Directions9
Field Cancerization Therapies for the Management of Actinic Keratosis: An Updated Review8
Beyond the Hot Comb: Updates in Epidemiology, Pathogenesis, and Treatment of Central Centrifugal Cicatricial Alopecia from 2011 to 20218
Psoriasis: Considerations for the Management of Women of Childbearing Potential8
Adherence to Hidradenitis Suppurativa Treatment8
Features and Long-Term Outcomes of Stage IV Melanoma Patients Achieving Complete Response Under Anti-PD-1-Based Immunotherapy8
Comment on: “Methotrexate Cutaneous Ulceration: A Systematic Review of Cases”8
Correction to: Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program8
Deucravacitinib for the Treatment of Psoriatic Disease8
A Guide to the Management of Hidradenitis Suppurativa in Pregnancy and Lactation7
Psychological Therapies and Mind–Body Techniques in the Management of Dermatologic Diseases: A Systematic Review7
Association of Cardiovascular Disease and Chronic Spontaneous Urticaria: A Case–Control Study7
Development and Validation of an Artificial Intelligence-Driven Model for Accurate Classification of Erythrodermic Psoriasis Severity: Erythrodermic Psoriasis Integrated Classification System (EPICS)7
Understanding Enthesitis in Psoriatic Disease: Insights and Implications7
Relationship of Histopathologic Parameters and Gene Expression Profiling in Malignant Melanoma7
Early and Sustained Improvements in Symptoms and Quality of Life with Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: 52-Week Results from Two Phase III Randomized Cl7
Pruritus in Pregnancy7
Lebrikizumab for the Treatment of Moderate-to-Severe Atopic Dermatitis7
Secukinumab in Pediatric Patients with Plaque Psoriasis: Pooled Safety Analysis from Two Phase 3 Randomized Clinical Trials7
Evaluating the Longitudinal Course of Atopic Dermatitis: Implications for Clinical Practice6
Stasis Dermatitis: An Overview of Its Clinical Presentation, Pathogenesis, and Management6
American Academy of Dermatology Annual Meeting: San Diego, CA, USA, 8–12 March 20246
Clinical Efficacy and Safety of Interleukin-17 Inhibitors in Treating Patients with Erythrodermic Psoriasis: A Retrospective Cohort, Three-Center Study6
Upadacitinib Versus Acitretin for the Resolution of Pustules in Palmoplantar Pustulosis During Acute Phase: A Single-Center, Open-Label Prospective Cohort Study6
Hidradenitis Suppurativa: New Targets and Emerging Treatments6
Publisher Correction to: Multiple Keratoacanthomas Associated with Genetic Syndromes: Narrative Review and Proposal of a Diagnostic Algorithm6
Maximal Usage Trial of Tapinarof Cream 1% Once Daily in Pediatric Patients Down to 2 Years of Age with Extensive Atopic Dermatitis6
Lactobacillus rhamnosus Used in the Perinatal Period for the Prevention of Atopic Dermatitis in Infants: A Systematic Review and Meta-Analysis of Randomized Trials6
Efficacy and Safety of Brodalumab, an Anti-interleukin-17 Receptor A Monoclonal Antibody, for Palmoplantar Pustulosis: 16-Week Results of a Randomized Clinical Trial6
Acknowledgment to Referees6
Efficacy and Safety of Abrocitinib in Patients with Severe and/or Difficult-to-Treat Atopic Dermatitis: A Post Hoc Analysis of the Randomized Phase 3 JADE COMPARE Trial6
Guselkumab-Treated Patients with Plaque Psoriasis Who Achieved Complete Skin Clearance for ≥ 156 Consecutive Weeks: A Post-Hoc Analysis From the VOYAGE 1 Clinical Trial6
Development of Cutaneous T-Cell Lymphoma Following Biologic Treatment: A Systematic Review6
Sequencing of Targeted Therapy in Psoriasis: Does it Matter?6
Global Incidence, Mortality, Risk Factors and Trends of Melanoma: A Systematic Analysis of Registries6
Correction to: Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program6
0.25105214118958